Physician profile
Ryan Parker
NPI 1912478231
$3,983.80
in general payments reported to CMS, 2019-2025
26 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $520 · 2023: $763 · 2024: $1,091 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Consulting Fee: $630 · Education: $180 · Travel and Lodging: $49.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.69 |
| Consulting Fee | $630.00 |
| Education | $179.93 |
| Travel and Lodging | $49.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,097.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $922.63 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $420.49 | 2023-2025 | Dupixent |
| Philips North America LLC | $281.78 | 2021-2025 | (8874) Incourage, Vest Therapy Und, Encore |
| Glaxosmithkline, LLC. | $244.78 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Harmony Biosciences LLC | $187.63 | 2023-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.01 | 2022-2024 | Ofev, Spiriva Respimat |
| Resmed Corp | $85.42 | 2023-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $72.69 | 2024 | Lumryz |
| Jazz Pharmaceuticals INC. | $62.78 | 2021-2022 | |
| Baxter Healthcare | $55.25 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $47.13 | 2022-2024 | Yupelri |
| Insmed, INC. | $46.19 | 2022-2024 | Arikayce |
| Verona Pharma, INC. | $44.32 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $40.34 | 2022-2023 | Prolastin-C Liquid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.82 | 2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $36.59 | 2023-2024 | Sunosi |
| Apria Healthcare LLC | $30.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.23 | 2023 | Glassia |
| Amgen INC. | $23.24 | 2022 | |
| Gilead Sciences, INC. | $21.77 | 2023 | Veklury |
| Vapotherm INC | $17.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.22 | 2022 | |
| Viatris Specialty LLC | $16.96 | 2025 | Yupelri |
| Electromed, INC. | $12.16 | 2022 | |
| Organogenesis INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.